Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-04, Stock:LLY, The news for the past five days is as follows:
2019-01-28: NEWS1: Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?.NEWS2: Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results.NEWS3: Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results.NEWS4: Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results.NEWS5: The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck.NEWS6: The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck.NEWS7: The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck.
2019-01-29: NEWS1: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS2: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS3: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS4: Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain.NEWS5: Pfizer, Lilly Announce Results From Phase 3 Study Of Tanezumab In OA Pain.NEWS6: Pfizer, Lilly Announce Results From Phase 3 Study Of Tanezumab In OA Pain.NEWS7: Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?.NEWS8: Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?.
2019-01-30: NEWS1: Lilly Revises Date for Fourth-Quarter 2018 Financial Results Announcement.NEWS2: U.S. lawmakers request info from insulin makers on rising prices.NEWS3: House Democratic leaders probe 3 major drugmakers on insulin prices.NEWS4: Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study.NEWS5: Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study.NEWS6: Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study.NEWS7: Amgen Leaves Investors With Mixed Emotions.NEWS8: Amgen Leaves Investors With Mixed Emotions.
2019-01-31: NEWS1: This Pharma Stock Broke Out On Its Merck-Partnered Cancer Regimen.NEWS2: Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?.NEWS3: Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?.NEWS4: Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?.NEWS5: FDA Expands Lilly's ALIMTA® (pemetrexed) Label with Combination of KEYTRUDA® (pembrolizumab) and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer.
2019-02-01: NEWS1: Cramer&apos;s game plan: Be ready to &apos;buy the next dip&apos; in this &apos;ideal backdrop for stocks&apos;.NEWS2: Cramer's game plan: Be ready to 'buy the next dip' in this 'ideal backdrop for stocks'.NEWS3: Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva.NEWS4: Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat.NEWS5: Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat.NEWS6: Notable ETF Inflow Detected - XLV, AMGN, ABBV, LLY.NEWS7: Notable ETF Inflow Detected - XLV, AMGN, ABBV, LLY.NEWS8: Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat.NEWS9: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS10: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS11: Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY.NEWS12: Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY.NEWS13: Pharma Catches Another Case Of M&A Fever.NEWS14: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS15: The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of Titan's Opioid Disorder Treatment Implant.NEWS16: Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY.NEWS17: Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction.NEWS18: Eli Lilly, Loxo Oncology Report Expiration Of HSR Act Waiting Period.NEWS19: Eli Lilly, Loxo Oncology Report Expiration Of HSR Act Waiting Period.NEWS20: J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study.NEWS21: J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study.NEWS22: J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study.

Answer: Decrease